Abstracts Archive - Page 1310 of 2607 - ACR Meeting Abstracts

Abstract Number: 1855 • 2018 ACR/ARHP Annual Meeting
Erythrocyte Bound C4d in the Presence of Adverse Pregnancy Outcome Events in Pregnant Women with Systemic Lupus Erythematosus
Jill P. Buyon¹, Peter M. Izmirly², H. Michael Belmont³, John Conklin⁴, Nicole Kaiden⁵, Jane E. Salmon⁶, Roberta Alexander⁴ and Thierry Dervieux⁴, ¹Medicine, New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, NY, ³Medicine, NYU Langone Health, New York, NY, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶Medicine/Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Activation of the alternative and terminal attack complex of the complement system has been associated with adverse pregnancy outcomes (APOs) in stable/quiescent systemic lupus…
Abstract Number: 1856 • 2018 ACR/ARHP Annual Meeting
Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort
Arielle Mendel, Sasha Bernatsky and Evelyne Vinet, Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Because aspirin reduces the risk of preeclampsia in high-risk pregnancies by more than half, best practice guidelines recommend that aspirin be initiated in pregnant…
Abstract Number: 1857 • 2018 ACR/ARHP Annual Meeting
Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss
Meiying Wang^1,2, Peng Zhang³, gengmin zhou¹, jiyang lv¹, chengshan guo⁴ and Qingwen Wang¹, ¹Rheumatology and Immunology, Peking University Shenzhen Hospital, shenzhen, China, ²Rheumtology, David Geffen school of Medicine at UCLA, Los Angeles, CA, ³SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES, shenzhen, China, ⁴Rheumatology and Immunology, The people's Hospital of Bao’an District Shenzhen City., shenzhen, China
Background/Purpose: Type 1/type 2 T helper (Th1/Th2) cells and their cytokines are implicated in the pathogenesis of autoimmune diseases[1]; however, their roles in antiphospholipid antibody-associated…
Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
Abstract Number: 1859 • 2018 ACR/ARHP Annual Meeting
The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Alexander Platzer², Farideh Alasti², Paul Studenic³, Maresa Grundhuber⁴, Sascha Swiniarski⁴, Stephan Blüml², Helmuth Haslacher⁵, Josef S. Smolen⁶ and Günter Steiner¹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ⁵Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). Lately we showed that the determination…
Abstract Number: 1860 • 2018 ACR/ARHP Annual Meeting
Development and Validation of a Microrna Panel to Differentiate between Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Control Subjects
Michelle J. Ormseth, Joseph F. Solus, Quanhu Sheng, Fei Ye, Qiong Wu, Yan Guo, Annette M. Oeser, Ryan Allen, Kasey Vickers and C Michael Stein, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: MicroRNAs (miRNAs) are short non-coding RNAs that regulate genes and have utility as disease biomarkers. Use of small RNA (sRNA) sequencing along with unbiased…
Abstract Number: 1861 • 2018 ACR/ARHP Annual Meeting
Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis
Nikila Kumar¹, Wei-Hsuan Lo-Ciganic², Lili Zhou^3,4, Erin L. Ashbeck⁴ and C. Kent Kwoh^1,4, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ³College of Pharmacy, University of Arizona, Tucson, AZ, ⁴University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Patients with RA have an increased risk of cardiovascular disease (CVD) accounting for over 50% of premature deaths in the RA population. EULAR recommends…
Abstract Number: 1862 • 2018 ACR/ARHP Annual Meeting
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Very Low Circulating Low-Density Lipoprotein Concentration Levels Are Associated with Pro-Atherogenic Biomarkers
Jon T. Giles¹, Cecilia P. Chung², Mary Chester-Wasko³, Mike Centola⁴, Jenny Van Eyk⁵, Justyna Fert-Bober⁵, Amy Kao⁶, Annette M. Oeser⁷, C. Michael Stein² and Joan Bathon⁸, ¹Medicine/Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ³Allegheny Health Network, Pittsburgh, PA, ⁴Haus Bioceuticals, Inc, Oklahoma City, OK, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Biogen, Cambridge, MA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients with very low levels of circulating low density lipoprotein cholesterol (LDL-C) have been reported to be at particularly high risk…
Abstract Number: 1863 • 2018 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibody at Multiple Cutoff Levels and in Combination with Rheumatoid Factor IgM and Serum Calprotectin Is Highly Specific for the Development of Rheumatoid Arthritis within 3 Years
Leah F. Bettner¹, Lindsay B. Kelmenson¹, M. Kristen Demoruelle¹, Ted R. Mikuls², Jess Edison³, Elizabeth A. Mewshaw⁴, Mark C. Parish¹, Marie L. Feser¹, Ashley A. Frazer-Abel¹, LauraKay Moss¹, Michael Mahler⁵, V. Michael Holers⁶ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Research and Development, Inova Diagnostics, San Diego, CA, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Serum elevations of antibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF) can identify individuals at risk for developing rheumatoid arthritis (RA). Prior…
Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Désirée van der Heijde¹, James Cheng-Chung Wei², Maxime Dougados³, Philip J. Mease⁴, Atul A. Deodhar⁵, Walter P. Maksymowych⁶, Filip van Den Bosch⁷, Joachim Sieper⁸, Tetsuya Tomita⁹, Robert B.M. Landewé¹⁰, Lotus Mallbris¹¹, Fangyi Zhao¹¹, David Adams¹¹, Beth Pangallo¹¹ and Hilde Carlier¹¹, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Oregon Health & Science U, Portland, OR, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁸Charité University Hospital, Berlin, Germany, ⁹Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁰Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
Abstract Number: 1865 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active As/Radiographic Axial Spa Naive to Biologic DMARD Therapy: 16‑Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen^3,4, Lianne S. Gensler⁵, Theresa Hunter⁶, Fangyi Zhao⁶, Hilde Carlier⁶ and Jürgen Braun^1,7, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Caphri Research Institute, Maastricht, Netherlands, ⁵School of Medicine, UCSF, San Francisco, CA, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Ruhr Universität Bochum, Bochum, Germany
Background/Purpose: The Assessment of SpA international Society Health Index (ASAS HI) is a relatively new measure to assess function, disability, and health in patients with…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Johan Askling², Adrian Ciurea³, Eirik K Kristianslund⁴, Fatos Onen⁵, Dan Nordström⁶, Maria José Santos⁷, Catalin Codreanu⁸, Ziga Rotar⁹, Björn Gudbjornsson¹⁰, Daniela Di Giuseppe², Michael J. Nissen¹¹, Tore Kvien⁴, Merih Birlik⁵, Nina Trokovic⁶, Anabela Barcelos⁷, Ruxandra Ionescu⁸, Matija Tomšič⁹, Arni Jon Geirsson¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Tamara Rusman¹³, Juan J. Gomez-Reino¹⁴, Gareth T. Jones¹⁵, Florenzo Iannone¹⁶, Karel Pavelka¹², Irene van der Horst-Bruinsma¹⁷, Lise Hyldstrup¹, Niels Steen Krogh¹⁸, Merete Lund Hetland¹ and Mikkel Østergaard¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁸RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ⁹biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ¹⁰ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ¹¹SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, ¹⁴BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁵BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁶GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁷ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁸Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…
Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Atul A. Deodhar¹, Lianne S. Gensler², Jonathan Kay³, Walter P. Maksymowych⁴, Nigil Haroon⁵, Robert B.M. Landewé⁶, Martin Rudwaleit⁷, Stephen Hall⁸, Lars Bauer⁹, Bengt Hoepken⁹, Natasha de Peyrecave¹⁰, Brian Kilgallen¹¹ and Désirée van der Heijde¹², ¹Oregon Health and Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, ⁸Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
Abstract Number: 1869 • 2018 ACR/ARHP Annual Meeting
Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study
Alan J. Kivitz¹, Karel Pavelka², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Yi Wang⁷, Brian Porter⁸, Anna Stefanska⁹, Susanne Rohrer¹⁰ and Hanno Richards¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²1st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o.,, Uherske Hradiste, Czech Republic, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Ireland Limited, Dublin, Ireland, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 3 study, which…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].